source
- Argenx reports positive Phase 3 results for Vyvgart Hytrulo in myositisArgenx announced that its subcutaneous formulation of Vyvgart, named Vyvgart Hytrulo, met the primary endpoint in a late‑stage Phase 3 trial in patients with myositis. The trial combined participa…
- AstraZeneca halts Phase 3 lung cancer trial of bispecific antibody volrustomig after interim data miss survival goalAstraZeneca announced termination of the Phase 3 study of its experimental bispecific antibody volrustomig in non‑small cell lung cancer. An interim data review by trial monitors indicated the dru…